Richard Kender joins Poxel's board of directors
This article was originally published in Scrip
Executive Summary
Lyon, France-based Poxel, a biopharmaceutical company developing drugs to treat type 2 diabetes, has named Richard N Kender to its board of directors as an independent board member. Most recently Mr Kender was senior vice-president of business development and corporate licensing at Merck & Co.